Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Recruiting 3Active not recruiting 3Terminated 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 32Myeloid 13Lymphoid 10Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

avatrombopag 4iron isomaltoside 1000 3hetrombopag 3ferric carboxymaltose 3Cytarabine 3eltrombopag 2Rivaroxaban 2Radiotherapy 2Meropenem 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Erythropoietin 2Cyclophosphamide 2thymoglobulin 1stinging nettle lectin 1romiplostim 1raltitrexed 1peppermint oil 1pegfilgrastim 1oprelvekin 1fludarabine phosphate 1fludarabine 1ferrous succinate 1ferrous fumarate 1ferric derisomaltose 1epoetin beta 1Vitamin B 12 1Vancomycin 1Valproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Azacitidine × Classical hematology × Clear all
NCT02124174 2021-04-26

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Loyola University

Phase 2 Unknown
50 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡